US20230330325A1 - Drug delivery device with electromagnetic drive unit - Google Patents
Drug delivery device with electromagnetic drive unit Download PDFInfo
- Publication number
- US20230330325A1 US20230330325A1 US18/337,625 US202318337625A US2023330325A1 US 20230330325 A1 US20230330325 A1 US 20230330325A1 US 202318337625 A US202318337625 A US 202318337625A US 2023330325 A1 US2023330325 A1 US 2023330325A1
- Authority
- US
- United States
- Prior art keywords
- coils
- coil
- armature
- inductance
- magnets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000012377 drug delivery Methods 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 22
- 230000005291 magnetic effect Effects 0.000 claims description 16
- 230000035699 permeability Effects 0.000 claims description 9
- 239000003990 capacitor Substances 0.000 claims description 5
- 238000004804 winding Methods 0.000 claims description 5
- 230000010363 phase shift Effects 0.000 claims description 3
- 230000003068 static effect Effects 0.000 claims description 2
- 230000000977 initiatory effect Effects 0.000 claims 5
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 54
- 108010011459 Exenatide Proteins 0.000 description 50
- 229960001519 exenatide Drugs 0.000 description 50
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 22
- QEFRNWWLZKMPFJ-YGVKFDHGSA-N L-methionine S-oxide Chemical compound CS(=O)CC[C@H](N)C(O)=O QEFRNWWLZKMPFJ-YGVKFDHGSA-N 0.000 description 22
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 21
- 229910052751 metal Inorganic materials 0.000 description 16
- 239000002184 metal Substances 0.000 description 16
- 229940079593 drug Drugs 0.000 description 13
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 239000012634 fragment Substances 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000010586 diagram Methods 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000011162 core material Substances 0.000 description 3
- 230000005294 ferromagnetic effect Effects 0.000 description 3
- 239000003302 ferromagnetic material Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000003055 low molecular weight heparin Substances 0.000 description 3
- 229940127215 low-molecular weight heparin Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 230000004323 axial length Effects 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000001831 (C6-C10) heteroaryl group Chemical group 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 229910052779 Neodymium Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 108010010056 Terlipressin Proteins 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 206010057362 Underdose Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005153 enoxaparin sodium Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 108010015174 exendin 3 Proteins 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- XVVOERDUTLJJHN-IAEQDCLQSA-N lixisenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 XVVOERDUTLJJHN-IAEQDCLQSA-N 0.000 description 1
- 108010004367 lixisenatide Proteins 0.000 description 1
- 229960001093 lixisenatide Drugs 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 description 1
- 229910001172 neodymium magnet Inorganic materials 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960004532 somatropin Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 241001223854 teleost fish Species 0.000 description 1
- 229960003813 terlipressin Drugs 0.000 description 1
- BENFXAYNYRLAIU-QSVFAHTRSA-N terlipressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1 BENFXAYNYRLAIU-QSVFAHTRSA-N 0.000 description 1
- CIJQTPFWFXOSEO-NDMITSJXSA-J tetrasodium;(2r,3r,4s)-2-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(1r,2r,3r,4r)-4-[(2r,3s,4r,5r,6r)-5-acetamido-6-[(4r,5r,6r)-2-carboxylato-4,5-dihydroxy-6-[[(1r,3r,4r,5r)-3-hydroxy-4-(sulfonatoamino)-6,8-dioxabicyclo[3.2.1]octan-2-yl]oxy]oxan-3-yl]oxy-2-(hydroxy Chemical compound [Na+].[Na+].[Na+].[Na+].O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1O)NC(C)=O)O[C@@H]1C(C[C@H]([C@@H]([C@H]1O)O)O[C@@H]1[C@@H](CO)O[C@H](OC2C(O[C@@H](OC3[C@@H]([C@@H](NS([O-])(=O)=O)[C@@H]4OC[C@H]3O4)O)[C@H](O)[C@H]2O)C([O-])=O)[C@H](NC(C)=O)[C@H]1C)C([O-])=O)[C@@H]1OC(C([O-])=O)=C[C@H](O)[C@H]1O CIJQTPFWFXOSEO-NDMITSJXSA-J 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14212—Pumping with an aspiration and an expulsion action
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/30—Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or carpules
-
- H—ELECTRICITY
- H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
- H02K—DYNAMO-ELECTRIC MACHINES
- H02K11/00—Structural association of dynamo-electric machines with electric components or with devices for shielding, monitoring or protection
- H02K11/20—Structural association of dynamo-electric machines with electric components or with devices for shielding, monitoring or protection for measuring, monitoring, testing, protecting or switching
- H02K11/21—Devices for sensing speed or position, or actuated thereby
- H02K11/225—Detecting coils
-
- H—ELECTRICITY
- H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
- H02K—DYNAMO-ELECTRIC MACHINES
- H02K41/00—Propulsion systems in which a rigid body is moved along a path due to dynamo-electric interaction between the body and a magnetic field travelling along the path
- H02K41/02—Linear motors; Sectional motors
- H02K41/03—Synchronous motors; Motors moving step by step; Reluctance motors
- H02K41/031—Synchronous motors; Motors moving step by step; Reluctance motors of the permanent magnet type
-
- H—ELECTRICITY
- H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
- H02P—CONTROL OR REGULATION OF ELECTRIC MOTORS, ELECTRIC GENERATORS OR DYNAMO-ELECTRIC CONVERTERS; CONTROLLING TRANSFORMERS, REACTORS OR CHOKE COILS
- H02P25/00—Arrangements or methods for the control of AC motors characterised by the kind of AC motor or by structural details
- H02P25/02—Arrangements or methods for the control of AC motors characterised by the kind of AC motor or by structural details characterised by the kind of motor
- H02P25/06—Linear motors
-
- H—ELECTRICITY
- H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
- H02P—CONTROL OR REGULATION OF ELECTRIC MOTORS, ELECTRIC GENERATORS OR DYNAMO-ELECTRIC CONVERTERS; CONTROLLING TRANSFORMERS, REACTORS OR CHOKE COILS
- H02P25/00—Arrangements or methods for the control of AC motors characterised by the kind of AC motor or by structural details
- H02P25/02—Arrangements or methods for the control of AC motors characterised by the kind of AC motor or by structural details characterised by the kind of motor
- H02P25/06—Linear motors
- H02P25/064—Linear motors of the synchronous type
- H02P25/066—Linear motors of the synchronous type of the stepping type
-
- H—ELECTRICITY
- H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
- H02P—CONTROL OR REGULATION OF ELECTRIC MOTORS, ELECTRIC GENERATORS OR DYNAMO-ELECTRIC CONVERTERS; CONTROLLING TRANSFORMERS, REACTORS OR CHOKE COILS
- H02P8/00—Arrangements for controlling dynamo-electric motors rotating step by step
- H02P8/005—Arrangements for controlling dynamo-electric motors rotating step by step of linear motors
-
- H—ELECTRICITY
- H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
- H02P—CONTROL OR REGULATION OF ELECTRIC MOTORS, ELECTRIC GENERATORS OR DYNAMO-ELECTRIC CONVERTERS; CONTROLLING TRANSFORMERS, REACTORS OR CHOKE COILS
- H02P8/00—Arrangements for controlling dynamo-electric motors rotating step by step
- H02P8/34—Monitoring operation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
-
- H—ELECTRICITY
- H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
- H02P—CONTROL OR REGULATION OF ELECTRIC MOTORS, ELECTRIC GENERATORS OR DYNAMO-ELECTRIC CONVERTERS; CONTROLLING TRANSFORMERS, REACTORS OR CHOKE COILS
- H02P2203/00—Indexing scheme relating to controlling arrangements characterised by the means for detecting the position of the rotor
- H02P2203/01—Motor rotor position determination based on the detected or calculated phase inductance, e.g. for a Switched Reluctance Motor
Definitions
- the disclosure relates to a drive unit, in particular for a drug delivery device.
- Administering an injection is a process which presents a number of risks and challenges for users and healthcare professionals, both mental and physical.
- Injection devices i.e. devices capable of delivering medicaments from a medication container
- Injection devices typically fall into two categories — manual devices and auto-injectors.
- a manual device the user must provide the mechanical energy to drive the fluid through the needle. This is typically done by some form of button / plunger that has to be continuously pressed by the user during the injection. There are numerous disadvantages to the user from this approach. If the user stops pressing the button / plunger, then the injection will also stop. This means that the user can deliver an underdose if the device is not used properly (i.e. the plunger is not fully pressed to its end position). Injection forces may be too high for the user, in particular if the patient is elderly or has dexterity problems.
- the extension of the button/plunger may be too great. Thus it can be inconvenient for the user to reach a fully extended button.
- the combination of injection force and button extension can cause trembling / shaking of the hand which in turn increases discomfort as the inserted needle moves.
- Auto-injector devices aim to make self-administration of injected therapies easier for patients.
- Current therapies delivered by means of self-administered injections include drugs for diabetes (both insulin and newer GLP-1 class drugs), migraine, hormone therapies, anticoagulants etc.
- Auto-injectors are devices which completely or partially replace activities involved in parenteral drug delivery from standard syringes. These activities may include removal of a protective syringe cap, insertion of a needle into a patient’s skin, injection of the medicament, removal of the needle, shielding of the needle and preventing reuse of the device.
- This overcomes many of the disadvantages of manual devices. Injection forces / button extension, hand-shaking and the likelihood of delivering an incomplete dose are reduced.
- Triggering may be performed by numerous means, for example a trigger button or the action of the needle reaching its injection depth.
- the energy to deliver the fluid is provided by a drive unit such as a spring or an electric motor.
- the present disclosure provides an improved drive unit, in particular for a drug delivery device.
- a drive unit comprises:
- the drive unit may thus be applied as a linear actuator in a drug delivery device, e.g. by applying an alternating voltage to the coils.
- the at least one terminal pole shoe differs from the pole shoes in its geometry, in particular in its axial length such that one of the coils, in which the terminal pole shoe is located has a different inductance than any one of the coils, in which one of the pole shoes is located.
- a control unit is connected to the individual coils for determining their inductance, wherein the control unit is adapted to determine an axial position of the armature within the stator from the determined inductances.
- the drive unit is thus used for both, driving the armature and determining its axial position such that no further sensor is required.
- the stator further comprises a plurality of notched metal sheets in an alternating arrangement with the coils.
- the magnets are axially magnetized.
- consecutive ones of the magnets exhibit alternating magnetic polarities.
- the drive unit is applied in a drug delivery device, further comprising a drug cartridge with a stopper slidably arranged within the cartridge, wherein the armature abuts the stopper.
- the drive unit can thus be used for displacing the stopper and dispensing a dose of drug from the cartridge.
- the drive unit can be used to determine the position of the armature and hence the stopper in order to determine an amount of drug already delivered and/or an amount of drug remaining in the cartridge.
- the coils of the stator are subdivided into a first group and a second group, the first group extending proximally from the cartridge along a distance corresponding to a length of the armature, wherein the second group is coaxially arranged over at least a substantial part of the length of the cartridge, wherein the second group of coils has an increased air gap between the notched metal sheets and the pole shoes compared to the first group in order to allow insertion of the cartridge.
- the air gap between the first group and the armature is less than 1 mm thus efficiently using the available space and achieving a high degree of efficiency.
- the magnetic latching forces and thrust forces acting on the armature are significantly determined by the air gap between the notched metal sheets and the pole shoes. This allows for a precise adaptation to the requested thrust parameters in the operating area of the first group.
- an inner diameter of notches varies such that a gradient of thrust forces or latching forces acting on the armature converges to a given characteristic line.
- the restriction line is linearly decaying.
- a relation between an external diameter of the stator and an external diameter of the cartridge is within a range from 1.5 to 3, in particular 2.2.
- a relation between an external diameter of the armature and an internal diameter of the stator is within a range from 0.8 to 0.99, in particular 0.95.
- a relation between a length of one of the poles shoes and a length of one of the terminal pole shoes is within a range from 0.3 to 0.5, in particular 0.43 and/or a magnetic permeability of one of the pole shoes differs from a magnetic permeability of one of the terminal pole shoes.
- the inductances of two adjacent coils may significantly differ as the terminal pole show passes such that the position of the armature can be more precisely determined.
- a relation between the air gap in the operating range of the first group of coils and an external diameter of the cartridge is within a range from 0.01 to 0.05, in particular 0.02.
- FIG. 1 is a schematic longitudinal section of an exemplary embodiment of a drug delivery device with a drive unit comprising an armature, a first group of coils and a second group of coils,
- FIG. 2 is a diagram of forces exerted on the armature by the first group of coils depending on an axial position of the armature
- FIG. 3 is a schematic sectional detail view of the drive unit
- FIG. 4 is a diagram of a thrust force exerted on the armature by the second group of coils depending on the axial position of the armature, and
- FIG. 5 is a diagram of an inductance of a coil depending on the axial position of the armature.
- FIG. 1 is a schematic longitudinal section of an exemplary embodiment of a drug delivery device 1 .
- the drug delivery device 1 comprises an elongate case 2 , a cartridge holder 3 , a drug cartridge 4 and a drive unit 5 .
- the case 2 may have a tubular shape.
- the cartridge holder 3 may be axially and radially fixed to the case 2 .
- the drug cartridge 4 may be arranged as an ampoule or syringe adapted to be connected to a nozzle such as a hypodermic needle or having an attached nozzle.
- the cartridge 4 may comprise or consist of glass or a plastic material.
- a stopper 6 is slidably arranged within the cartridge 4 so as to seal the cartridge 4 proximally and allow displacement of a drug held within the cartridge 4 on translation of the stopper 6 in a distal direction D relative to the cartridge 4 .
- the nozzle may also be arranged as a jet nozzle for needleless injection or as a spray nozzle.
- the cartridge 4 is replaceable.
- the drive unit 5 comprises a stator 7 and an armature 8 axially movable within the stator 7 and arranged to abut the stopper 6 .
- the stator 7 comprises a ferromagnetic tube 9 also serving as the case 2 in the illustrated embodiment.
- the tube 9 may be axially split such that it comprises two axially aligned tube sections.
- these internal components may be fixed to the tube 9 in a different way.
- the stator 7 furthermore comprises a number of coils 12 , e.g. copper coils, and notched metal sheets 13 in an alternating arrangement such that a metal sheet 13 is axially followed by a coil 12 , another metal sheet 13 and another coil 12 and so on.
- the stator comprises 21 coils 12 and 22 notched metal sheets 13 .
- the skilled person will understand that any other number of coils and notched metal sheets 13 may be arranged. However, in an exemplary embodiment, the number of notched metal sheets 13 exceeds the number of coils 12 by one.
- the armature 8 comprises a number of axially magnetized magnets 14 , e. g. rare earth magnets such as neodymium magnets comprising iron and neodymium. A number of these magnets 14 are consecutively arranged along an axial direction with alternating magnetic polarity. A respective pole shoe 15 comprising or consisting of a ferromagnetic material is arranged between neighbouring magnets 14 and a respective terminal pole shoe 16 comprising or consisting of a ferromagnetic material at each axial end of the sequence of magnets 14 and pole shoes 15 .
- rare earth magnets such as neodymium magnets comprising iron and neodymium.
- a number of these magnets 14 are consecutively arranged along an axial direction with alternating magnetic polarity.
- a respective pole shoe 15 comprising or consisting of a ferromagnetic material is arranged between neighbouring magnets 14 and a respective terminal pole shoe 16 comprising or consisting of a ferromagnetic material at each axial
- the pole shoes 15 , terminal pole shoes 16 and the magnets 14 may have central bores allowing them to be arranged on a non-ferromagnetic axle 17 which may comprise or consist of a non-ferromagnetic stainless steel.
- a protective layer such as a heat shrink hose may be arranged over the armature 8 for mechanically protecting the armature 8 .
- the armature 8 comprises four magnets 14 , three pole shoes 15 and two terminal pole shoes 16 .
- the skilled person will understand that any other number of magnets 14 , pole shoes 15 and terminal pole shoes 16 may be arranged. However, preferable the number of pole shoes 15 and terminal pole shoes 16 exceeds the number of magnets 14 by one.
- the terminal pole shoes 16 differ from the pole shoes 15 in their geometry, in particular in their axial length.
- the terminal pole shoes 16 may be used for determining an axial position of the armature 8 .
- the material of the terminal pole shoes 16 may differ from the material of the pole shoes 15 in its magnetic permeability to generate a different, e.g. higher, inductance.
- the coils 12 and notched metal sheets 13 of the stator 7 are subdivided into a first group 19 and a second group 20 .
- the first group 19 extends proximally behind the cartridge 4 along a distance corresponding to the length of the armature 8 .
- the second group 20 is coaxially arranged over at least a substantial part of the length of the cartridge 4 such as approximately 80% of this length. The skilled person will understand that the second group 20 may extend over any other fraction of the length of the cartridge 4 or over its full length.
- the first group 19 comprises eight coils 12 and nine metal sheets 13 and the second group comprises 13 coils 12 and 14 metal sheets 13 , wherein the first group 19 and the second group 20 share one of the metal sheets 13 where they adjoin each other.
- the first group 19 serves for guiding the armature 8 and is arranged for generating an external magnetic field for advancing the armature 8 when the cartridge 4 is full.
- An air gap 21 between the first group 19 and the armature 8 is particularly small, e. g. less than 1 mm, thus efficiently using the available space and achieving a high degree of efficiency.
- the magnetic latching forces and thrust forces acting on the armature 8 are significantly determined by the air gap 21 between the notched metal sheets 13 and the pole shoes 15 , 16 . This allows for a precise adaptation to the requested thrust parameters in the operating area of the first group 19 .
- the minimum latching forces of the armature may be lower than 1 N when the coils 12 are turned off, the thrust forces may be higher than 20N when the coils 12 are supplied with a current.
- FIG. 2 is a diagram of forces F exerted on the armature 8 by the first group 19 of coils 12 depending on an axial position L of the armature 8 relative to the stator 7 .
- FIG. 3 is a schematic sectional detail view of the drive unit 5 .
- An inner diameter d l of notches created by the notched metal sheets 13 may be separately varied such that the gradient of the thrust forces F T or the latching forces F L converges to a given characteristic line.
- the thrust forces F T converge to a linearly decaying restriction line R when the coils 12 are supplied with a current.
- the latching forces F L are predominantly negative such that the armature moves to a zero position when the coils 12 are turned off thus providing a safety function.
- FIG. 4 is a diagram of the thrust force F T exerted on the armature 8 by the second group 20 of coils 12 depending on the axial position of the armature 8 relative to the stator 7 .
- the latching forces F L achievable in the operating area of the second group 20 are lower than in the operating area of the first group 19 .
- all notches and coils 12 have an identical inner diameter.
- the geometrical parameters of the drug delivery device 1 are selected such that a relation of the thrust force F T to the latching force F L is within a range from 15 to 40 , in particular 20 .
- the geometrical relations of the drug delivery device 1 may be as follows:
- a relation between an external diameter of the stator 7 and an external diameter of the cartridge 4 is within a range from 1.5 to 3, in particular 2.2.
- a relation between an external diameter of the armature 8 and the external diameter of the cartridge 4 is within a range from 0.5 to 0.9, in particular 0.8.
- a relation between the external diameter of the armature 8 and an internal diameter of the stator 7 is within a range from 0.8 to 0.99, in particular 0.95.
- a relation between a length of the stator 7 and a length of the cartridge 4 is within a range from 1 to 1.5, in particular 1.2.
- a relation between a length of the armature 8 and the length of the cartridge 4 is within a range from 0.3 to 0.9, in particular 0.61.
- a relation between a pole pitch length and the length of the armature 8 is within a range from 0.15 to 0.3, in particular 0.185.
- the pole pitch length is the sum of the lengths of one of the pole shoes 15 and an adjacent magnet 14 .
- a relation between the length of one of the poles shoes 15 and a length of one of the terminal pole shoes 16 is within a range from 0.3 to 0.5, in particular 0.43.
- a relation between the air gap 21 in the operating range of the first group 19 of coils 12 and the external diameter of the cartridge 4 is within a range from 0.01 to 0.05, in particular 0.02.
- the thrust force F T may be 20 N and the latching force F L may be 1 N.
- the axial position of the armature 8 and hence the dosing of the drug can be determined by measuring the inductance of the coils 12 within the stator 7 or by the fluctuation of this inductance.
- the inductance L of a long cylindrical coil 12 is determined by the geometry of the coil 12 and is calculated using equation 1 depending on a number N of windings, the magnetic field constant ⁇ o , the relative permeability ⁇ r and the internal cross-sectional area A of the coil 12 .
- a shorter cylindrical coil 12 exhibits a worse magnetic flux such that the inductance L is estimated by equation 2 additionally taking into account a radius of the winding r w .
- Ferromagnetic materials such as iron, which has a relative permeability in the range from 300 to 10000, can be used to increase the inductance L. Because of the linear dependence the inductance can be multiplied.
- FIG. 5 is a diagram of the inductance L of a number of subsequent coils 12 depending on the axial position of the armature 8 determined using a finite element model.
- the longer terminal pole shoe 16 at the end of the armature 8 causes an increase of the inductance L as opposed to the shorter pole shoes 15 arranged between the magnets 14 . This allows for a more precise determination of the position of the armature 8 .
- the relation of the variation of the inductance L due to the terminal pole shoe 16 to the variation of the inductance L due to the pole shoe 15 is within a range from 2 to 5 , in particular 3 .
- the variation of the inductance L due to the terminal pole shoe 16 is 150 ⁇ Hand the variation of the inductance L due to the pole shoe 15 is 50 ⁇ H.
- the coils 12 are supplied with an alternating or pulsed current such that magnetic fields are induced in the coils 12 and interact with the static magnetic fields generated by the magnets 14 of the armature 8 .
- the inductance is determined for the individual coils 12 , e.g. by a control unit 18 connected to the individual coils 12 .
- This can be achieved by any conventional method such as applying an alternating voltage to the coil 12 , determining an amplitude and phase shift of the resulting current and calculating the inductive reactance and hence the inductance.
- an alternating current may be driven through the coil 12 and an amplitude and phase shift of the resulting voltage can be determined.
- the coil 12 can be connected to a capacitor having a known capacitance to form a resonator whose resonance frequency can be determined by wobbling or by applying a pulse signal and analyzing the answer signal. The inductance can then be calculated from the determined resonance frequency.
- the coil 12 can be connected as part of a bridge network, e. g. a Maxwell bridge for determining the resonance frequency.
- the axial position of the armature 8 and hence the already dispensed dose and/or the dose remaining in the cartridge 4 can be determined.
- the inductance of the coils 12 may be determined by the same voltage used to apply the thrust force F T to the armature 8 .
- the drive unit 5 may be arranged without the geometrical differences between the pole shoes 15 and terminal pole shoes 16 but with the above described different air gaps 21 of the first group 19 and the second group 20 .
- drug or “medicament”, as used herein, means a pharmaceutical formulation containing at least one pharmaceutically active compound
- Insulin analogues are for example Gly(A21), Arg(B31), Arg(B32) human insulin; Lys(B3), Glu(B29) human insulin; Lys(B28), Pro(B29) human insulin; Asp(B28) human insulin; human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.
- Insulin derivatives are for example B29-N-myristoyl-des(B30) human insulin; B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl- ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-Y-glutamyl)-des(B30) human insulin; B29-N-(N-lithocholyl-Y-glutamyl)-des(B30) human insulin; B29-N-(w-carboxyheptadecanoyl)-des(B30) human insulin and B29-N-( ⁇ -carboxy
- Exendin-4 for example means Exendin-4(1-39), a peptide of the sequence H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-lle-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2.
- Exendin-4 derivatives are for example selected from the following list of compounds:
- Hormones are for example hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists as listed in Rote Liste, ed. 2008, Chapter 50, such as Gonadotropine (Follitropin, Lutropin, Choriongonadotropin, Menotropin), Somatropine (Somatropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Leuprorelin, Buserelin, Nafarelin, Goserelin.
- Gonadotropine Follitropin, Lutropin, Choriongonadotropin, Menotropin
- Somatropine Somatropin
- Desmopressin Terlipressin
- Gonadorelin Triptorelin
- Leuprorelin Buserelin
- Nafarelin Goserelin.
- a polysaccharide is for example a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra low molecular weight heparin or a derivative thereof, or a sulphated, e.g. a poly-sulphated form of the above-mentioned polysaccharides, and/or a pharmaceutically acceptable salt thereof.
- An example of a pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium.
- Antibodies are globular plasma proteins ( ⁇ 150 kDa) that are also known as immunoglobulins which share a basic structure. As they have sugar chains added to amino acid residues, they are glycoproteins.
- the basic functional unit of each antibody is an immunoglobulin (Ig) monomer (containing only one Ig unit); secreted antibodies can also be dimeric with two Ig units as with IgA, tetrameric with four Ig units like teleost fish IgM, or pentameric with five Ig units, like mammalian IgM.
- Ig immunoglobulin
- the Ig monomer is a “Y”-shaped molecule that consists of four polypeptide chains; two identical heavy chains and two identical light chains connected by disulfide bonds between cysteine residues. Each heavy chain is about 440 amino acids long; each light chain is about 220 amino acids long. Heavy and light chains each contain intrachain disulfide bonds which stabilize their folding. Each chain is composed of structural domains called Ig domains. These domains contain about 70-110 amino acids and are classified into different categories (for example, variable or V, and constant or C) according to their size and function. They have a characteristic immunoglobulin fold in which two ⁇ sheets create a “sandwich” shape, held together by interactions between conserved cysteines and other charged amino acids.
- Ig heavy chain There are five types of mammalian Ig heavy chain denoted by ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ .
- the type of heavy chain present defines the isotype of antibody; these chains are found in IgA, IgD, IgE, IgG, and IgM antibodies, respectively.
- Distinct heavy chains differ in size and composition; ⁇ and ⁇ contain approximately 450 amino acids and ⁇ approximately 500 amino acids, while ⁇ and ⁇ have approximately 550 amino acids.
- Each heavy chain has two regions, the constant region (C H ) and the variable region (V H ).
- the constant region is essentially identical in all antibodies of the same isotype, but differs in antibodies of different isotypes.
- Heavy chains ⁇ , a and ⁇ have a constant region composed of three tandem Ig domains, and a hinge region for added flexibility; heavy chains ⁇ and ⁇ have a constant region composed of four immunoglobulin domains.
- the variable region of the heavy chain differs in antibodies produced by different B cells, but is the same for all antibodies produced by a single B cell or B cell clone.
- the variable region of each heavy chain is approximately 110 amino acids long and is composed of a single Ig domain.
- a light chain has two successive domains: one constant domain (CL) and one variable domain (VL).
- CL constant domain
- VL variable domain
- the approximate length of a light chain is 211 to 217 amino acids.
- Each antibody contains two light chains that are always identical; only one type of light chain, K or ⁇ , is present per antibody in mammals.
- variable (V) regions are responsible for binding to the antigen, i.e. for its antigen specificity.
- VL variable light
- VH variable heavy chain
- CDRs Complementarity Determining Regions
- an “antibody fragment” contains at least one antigen binding fragment as defined above, and exhibits essentially the same function and specificity as the complete antibody of which the fragment is derived from.
- Limited proteolytic digestion with papain cleaves the Ig prototype into three fragments. Two identical amino terminal fragments, each containing one entire L chain and about half an H chain, are the antigen binding fragments (Fab).
- the Fc contains carbohydrates, complement-binding, and FcR-binding sites.
- F(ab′)2 is divalent for antigen binding.
- the disulfide bond of F(ab′)2 may be cleaved in order to obtain Fab′.
- the variable regions of the heavy and light chains can be fused together to form a single chain variable fragment (scFv).
- Pharmaceutically acceptable salts are for example acid addition salts and basic salts.
- Acid addition salts are e.g. HCl or HBr salts.
- Basic salts are e.g. salts having a cation selected from alkali or alkaline, e.g. Na+, or K+, or Ca2+, or an ammonium ion N+(R1)(R2)(R3)(R4), wherein R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1-C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10-heteroaryl group.
- solvates are for example hydrates.
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Power Engineering (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Anesthesiology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Vascular Medicine (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Combustion & Propulsion (AREA)
- Electromagnetism (AREA)
- Microelectronics & Electronic Packaging (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
The disclosure relates to a drug delivery device having a drive unit includes a stator comprising a plurality of coils consecutively arranged in an axial direction, and an armature axially movable within the stator, the armature including a number of magnets and pole shoes consecutively arranged in the axial direction. A respective pole shoe is arranged between respectively neighbouring magnets. At least one axial end of the armature comprises a terminal pole shoe.
Description
- This application is a continuation of U.S. Pat. Application No. 15/930,132, filed on May 12, 2020, which is a continuation of U.S. Pat. Application No. 15/538,729, filed on Jun. 22, 2017, which is a U.S. National Stage Application under 35 USC § 371 of International Application No. PCT/EP2015/080674, filed on Dec. 18, 2015, which claims priority to European Patent Application No. 14199552.2, filed on Dec. 22, 2014, the entire contents of which are incorporated herein by reference.
- The disclosure relates to a drive unit, in particular for a drug delivery device.
- Administering an injection is a process which presents a number of risks and challenges for users and healthcare professionals, both mental and physical.
- Injection devices (i.e. devices capable of delivering medicaments from a medication container) typically fall into two categories — manual devices and auto-injectors.
- In a manual device — the user must provide the mechanical energy to drive the fluid through the needle. This is typically done by some form of button / plunger that has to be continuously pressed by the user during the injection. There are numerous disadvantages to the user from this approach. If the user stops pressing the button / plunger, then the injection will also stop. This means that the user can deliver an underdose if the device is not used properly (i.e. the plunger is not fully pressed to its end position). Injection forces may be too high for the user, in particular if the patient is elderly or has dexterity problems.
- The extension of the button/plunger may be too great. Thus it can be inconvenient for the user to reach a fully extended button. The combination of injection force and button extension can cause trembling / shaking of the hand which in turn increases discomfort as the inserted needle moves.
- Auto-injector devices aim to make self-administration of injected therapies easier for patients. Current therapies delivered by means of self-administered injections include drugs for diabetes (both insulin and newer GLP-1 class drugs), migraine, hormone therapies, anticoagulants etc.
- Auto-injectors are devices which completely or partially replace activities involved in parenteral drug delivery from standard syringes. These activities may include removal of a protective syringe cap, insertion of a needle into a patient’s skin, injection of the medicament, removal of the needle, shielding of the needle and preventing reuse of the device. This overcomes many of the disadvantages of manual devices. Injection forces / button extension, hand-shaking and the likelihood of delivering an incomplete dose are reduced. Triggering may be performed by numerous means, for example a trigger button or the action of the needle reaching its injection depth. In some devices, the energy to deliver the fluid is provided by a drive unit such as a spring or an electric motor.
- There remains a need for an improved drive unit, in particular for a drug delivery device.
- The present disclosure provides an improved drive unit, in particular for a drug delivery device.
- According to the disclosure, a drive unit comprises:
- a stator comprising a plurality of coils consecutively arranged in an axial direction,
- an armature axially movable within the stator, the armature comprising a number of magnets and pole shoes consecutively arranged in the axial direction, wherein a respective pole shoe is arranged between respectively neighbouring magnets, wherein at least one axial end of the armature comprises a terminal pole shoe.
- The drive unit may thus be applied as a linear actuator in a drug delivery device, e.g. by applying an alternating voltage to the coils.
- In an exemplary embodiment, the at least one terminal pole shoe differs from the pole shoes in its geometry, in particular in its axial length such that one of the coils, in which the terminal pole shoe is located has a different inductance than any one of the coils, in which one of the pole shoes is located.
- In an exemplary embodiment, a control unit is connected to the individual coils for determining their inductance, wherein the control unit is adapted to determine an axial position of the armature within the stator from the determined inductances.
- Thus allows for determining an axial position of the armature within the stator by determining the inductances of the coils and locating the one with an inductance differing from all the other inductances. The drive unit is thus used for both, driving the armature and determining its axial position such that no further sensor is required.
- In an exemplary embodiment, the stator further comprises a plurality of notched metal sheets in an alternating arrangement with the coils.
- In an exemplary embodiment, the magnets are axially magnetized.
- In an exemplary embodiment, consecutive ones of the magnets exhibit alternating magnetic polarities.
- In an exemplary embodiment, the drive unit is applied in a drug delivery device, further comprising a drug cartridge with a stopper slidably arranged within the cartridge, wherein the armature abuts the stopper. The drive unit can thus be used for displacing the stopper and dispensing a dose of drug from the cartridge. Furthermore, the drive unit can be used to determine the position of the armature and hence the stopper in order to determine an amount of drug already delivered and/or an amount of drug remaining in the cartridge.
- In an exemplary embodiment, the coils of the stator are subdivided into a first group and a second group, the first group extending proximally from the cartridge along a distance corresponding to a length of the armature, wherein the second group is coaxially arranged over at least a substantial part of the length of the cartridge, wherein the second group of coils has an increased air gap between the notched metal sheets and the pole shoes compared to the first group in order to allow insertion of the cartridge.
- In an exemplary embodiment, the air gap between the first group and the armature is less than 1 mm thus efficiently using the available space and achieving a high degree of efficiency. The magnetic latching forces and thrust forces acting on the armature are significantly determined by the air gap between the notched metal sheets and the pole shoes. This allows for a precise adaptation to the requested thrust parameters in the operating area of the first group.
- In an exemplary embodiment, an inner diameter of notches varies such that a gradient of thrust forces or latching forces acting on the armature converges to a given characteristic line. In an exemplary embodiment the restriction line is linearly decaying.
- In an exemplary embodiment, a relation between an external diameter of the stator and an external diameter of the cartridge is within a range from 1.5 to 3, in particular 2.2.
- In an exemplary embodiment, a relation between an external diameter of the armature and an internal diameter of the stator is within a range from 0.8 to 0.99, in particular 0.95.
- In an exemplary embodiment, a relation between a length of one of the poles shoes and a length of one of the terminal pole shoes is within a range from 0.3 to 0.5, in particular 0.43 and/or a magnetic permeability of one of the pole shoes differs from a magnetic permeability of one of the terminal pole shoes. Thus, the inductances of two adjacent coils may significantly differ as the terminal pole show passes such that the position of the armature can be more precisely determined.
- In an exemplary embodiment, a relation between the air gap in the operating range of the first group of coils and an external diameter of the cartridge is within a range from 0.01 to 0.05, in particular 0.02.
- Further scope of applicability of the present disclosure will become apparent from the detailed description given hereinafter. However, it should be understood that the detailed description and specific examples, while indicating exemplary embodiments of the disclosure, are given by way of illustration only, since various changes and modifications within the spirit and scope of the disclosure will become apparent to those skilled in the art from this detailed description.
- The present disclosure will become more fully understood from the detailed description given hereinbelow and the accompanying drawings which are given by way of illustration only, and thus, are not limitive of the present disclosure, and wherein:
-
FIG. 1 is a schematic longitudinal section of an exemplary embodiment of a drug delivery device with a drive unit comprising an armature, a first group of coils and a second group of coils, -
FIG. 2 is a diagram of forces exerted on the armature by the first group of coils depending on an axial position of the armature, -
FIG. 3 is a schematic sectional detail view of the drive unit, -
FIG. 4 is a diagram of a thrust force exerted on the armature by the second group of coils depending on the axial position of the armature, and -
FIG. 5 is a diagram of an inductance of a coil depending on the axial position of the armature. - Corresponding parts are marked with the same reference symbols in all figures.
-
FIG. 1 is a schematic longitudinal section of an exemplary embodiment of a drug delivery device 1. The drug delivery device 1 comprises anelongate case 2, acartridge holder 3, adrug cartridge 4 and adrive unit 5. - In an exemplary embodiment, the
case 2 may have a tubular shape. Thecartridge holder 3 may be axially and radially fixed to thecase 2. Thedrug cartridge 4 may be arranged as an ampoule or syringe adapted to be connected to a nozzle such as a hypodermic needle or having an attached nozzle. In an exemplary embodiment, thecartridge 4 may comprise or consist of glass or a plastic material. Astopper 6 is slidably arranged within thecartridge 4 so as to seal thecartridge 4 proximally and allow displacement of a drug held within thecartridge 4 on translation of thestopper 6 in a distal direction D relative to thecartridge 4. The nozzle may also be arranged as a jet nozzle for needleless injection or as a spray nozzle. In an exemplary embodiment thecartridge 4 is replaceable. - The
drive unit 5 comprises astator 7 and anarmature 8 axially movable within thestator 7 and arranged to abut thestopper 6. Thestator 7 comprises aferromagnetic tube 9 also serving as thecase 2 in the illustrated embodiment. In an exemplary embodiment, thetube 9 may be axially split such that it comprises two axially aligned tube sections. Likewise, these internal components may be fixed to thetube 9 in a different way. Thestator 7 furthermore comprises a number ofcoils 12, e.g. copper coils, and notchedmetal sheets 13 in an alternating arrangement such that ametal sheet 13 is axially followed by acoil 12, anothermetal sheet 13 and anothercoil 12 and so on. In an exemplary embodiment, the stator comprises 21coils metal sheets 13. The skilled person will understand that any other number of coils and notchedmetal sheets 13 may be arranged. However, in an exemplary embodiment, the number of notchedmetal sheets 13 exceeds the number ofcoils 12 by one. - The
armature 8 comprises a number of axiallymagnetized magnets 14, e. g. rare earth magnets such as neodymium magnets comprising iron and neodymium. A number of thesemagnets 14 are consecutively arranged along an axial direction with alternating magnetic polarity. Arespective pole shoe 15 comprising or consisting of a ferromagnetic material is arranged between neighbouringmagnets 14 and a respectiveterminal pole shoe 16 comprising or consisting of a ferromagnetic material at each axial end of the sequence ofmagnets 14 and pole shoes 15. The pole shoes 15, terminal pole shoes 16 and themagnets 14 may have central bores allowing them to be arranged on anon-ferromagnetic axle 17 which may comprise or consist of a non-ferromagnetic stainless steel. A protective layer such as a heat shrink hose may be arranged over thearmature 8 for mechanically protecting thearmature 8. - In an exemplary embodiment, the
armature 8 comprises fourmagnets 14, threepole shoes 15 and two terminal pole shoes 16. The skilled person will understand that any other number ofmagnets 14, pole shoes 15 and terminal pole shoes 16 may be arranged. However, preferable the number ofpole shoes 15 and terminal pole shoes 16 exceeds the number ofmagnets 14 by one. - The terminal pole shoes 16 differ from the pole shoes 15 in their geometry, in particular in their axial length. The terminal pole shoes 16 may be used for determining an axial position of the
armature 8. Alternatively or additionally, the material of the terminal pole shoes 16 may differ from the material of the pole shoes 15 in its magnetic permeability to generate a different, e.g. higher, inductance. - The
coils 12 and notchedmetal sheets 13 of thestator 7 are subdivided into afirst group 19 and asecond group 20. In the illustrated embodiment, thefirst group 19 extends proximally behind thecartridge 4 along a distance corresponding to the length of thearmature 8. Thesecond group 20 is coaxially arranged over at least a substantial part of the length of thecartridge 4 such as approximately 80% of this length. The skilled person will understand that thesecond group 20 may extend over any other fraction of the length of thecartridge 4 or over its full length. In the illustrated embodiment thefirst group 19 comprises eightcoils 12 and ninemetal sheets 13 and the second group comprises 13coils metal sheets 13, wherein thefirst group 19 and thesecond group 20 share one of themetal sheets 13 where they adjoin each other. - The
first group 19 serves for guiding thearmature 8 and is arranged for generating an external magnetic field for advancing thearmature 8 when thecartridge 4 is full. Anair gap 21 between thefirst group 19 and thearmature 8 is particularly small, e. g. less than 1 mm, thus efficiently using the available space and achieving a high degree of efficiency. The magnetic latching forces and thrust forces acting on thearmature 8 are significantly determined by theair gap 21 between the notchedmetal sheets 13 and the pole shoes 15, 16. This allows for a precise adaptation to the requested thrust parameters in the operating area of thefirst group 19. In an exemplary embodiment, due to this adaptation the minimum latching forces of the armature may be lower than 1 N when thecoils 12 are turned off, the thrust forces may be higher than 20N when thecoils 12 are supplied with a current. -
FIG. 2 is a diagram of forces F exerted on thearmature 8 by thefirst group 19 ofcoils 12 depending on an axial position L of thearmature 8 relative to thestator 7.FIG. 3 is a schematic sectional detail view of thedrive unit 5. An inner diameter dl of notches created by the notchedmetal sheets 13 may be separately varied such that the gradient of the thrust forces FT or the latching forces FL converges to a given characteristic line. Referring again toFIG. 2 , the thrust forces FT converge to a linearly decaying restriction line R when thecoils 12 are supplied with a current. The latching forces FL (retraction forces) are predominantly negative such that the armature moves to a zero position when thecoils 12 are turned off thus providing a safety function. - As opposed to the
first group 19 thesecond group 20 ofcoils 12 has an increasedair gap 21 allowing insertion of thecartridge 4. Consequently, the power losses are greater in thesecond group 20 such that the achievable thrust forces FT are lower. Thesmaller air gap 21 of thefirst group 19 results in higher efficiency and higher forces.FIG. 4 is a diagram of the thrust force FT exerted on thearmature 8 by thesecond group 20 ofcoils 12 depending on the axial position of thearmature 8 relative to thestator 7. Likewise, the latching forces FL achievable in the operating area of thesecond group 20 are lower than in the operating area of thefirst group 19. In thesecond group 20 all notches and coils 12 have an identical inner diameter. - In exemplary embodiment, the geometrical parameters of the drug delivery device 1 are selected such that a relation of the thrust force FT to the latching force FL is within a range from 15 to 40, in particular 20. For this purpose, the geometrical relations of the drug delivery device 1 may be as follows:
- A relation between an external diameter of the
stator 7 and an external diameter of thecartridge 4 is within a range from 1.5 to 3, in particular 2.2. - A relation between an external diameter of the
armature 8 and the external diameter of thecartridge 4 is within a range from 0.5 to 0.9, in particular 0.8. - A relation between the external diameter of the
armature 8 and an internal diameter of thestator 7 is within a range from 0.8 to 0.99, in particular 0.95. - A relation between a length of the
stator 7 and a length of thecartridge 4 is within a range from 1 to 1.5, in particular 1.2. - A relation between a length of the
armature 8 and the length of thecartridge 4 is within a range from 0.3 to 0.9, in particular 0.61. - A relation between a pole pitch length and the length of the
armature 8 is within a range from 0.15 to 0.3, in particular 0.185. The pole pitch length is the sum of the lengths of one of the pole shoes 15 and anadjacent magnet 14. - A relation between the length of one of the poles shoes 15 and a length of one of the terminal pole shoes 16 is within a range from 0.3 to 0.5, in particular 0.43.
- A relation between the
air gap 21 in the operating range of thefirst group 19 ofcoils 12 and the external diameter of thecartridge 4 is within a range from 0.01 to 0.05, in particular 0.02. - In an exemplary embodiment, the thrust force FT may be 20 N and the latching force FL may be 1 N.
- The axial position of the
armature 8 and hence the dosing of the drug can be determined by measuring the inductance of thecoils 12 within thestator 7 or by the fluctuation of this inductance. - The inductance L of a long
cylindrical coil 12 is determined by the geometry of thecoil 12 and is calculated using equation 1 depending on a number N of windings, the magnetic field constant µo, the relative permeability µr and the internal cross-sectional area A of thecoil 12. -
- A shorter
cylindrical coil 12 exhibits a worse magnetic flux such that the inductance L is estimated byequation 2 additionally taking into account a radius of the winding rw. -
- In order to modify the inductance L different core materials with different relative permeability µr can be used in a coil. Ferromagnetic materials such as iron, which has a relative permeability in the range from 300 to 10000, can be used to increase the inductance L. Because of the linear dependence the inductance can be multiplied.
- If a movable core with a varying permeability such as the
armature 8 is placed into a coil, the inductance of the coil depends on the axial position of the core.FIG. 5 is a diagram of the inductance L of a number ofsubsequent coils 12 depending on the axial position of thearmature 8 determined using a finite element model. The longerterminal pole shoe 16 at the end of thearmature 8 causes an increase of the inductance L as opposed to theshorter pole shoes 15 arranged between themagnets 14. This allows for a more precise determination of the position of thearmature 8. - In an exemplary embodiment, the relation of the variation of the inductance L due to the
terminal pole shoe 16 to the variation of the inductance L due to thepole shoe 15 is within a range from 2 to 5, in particular 3. In an exemplary embodiment, the variation of the inductance L due to theterminal pole shoe 16 is 150 µHand the variation of the inductance L due to thepole shoe 15 is 50 µH. - In order to apply a thrust force FT onto the
armature 8 for advancing thestopper 6 and dispensing a dose of the drug from thecartridge 4, thecoils 12 are supplied with an alternating or pulsed current such that magnetic fields are induced in thecoils 12 and interact with the static magnetic fields generated by themagnets 14 of thearmature 8. - In order to determine the axial position of the
armature 8 within thestator 7 the inductance is determined for theindividual coils 12, e.g. by acontrol unit 18 connected to the individual coils 12. This can be achieved by any conventional method such as applying an alternating voltage to thecoil 12, determining an amplitude and phase shift of the resulting current and calculating the inductive reactance and hence the inductance. Likewise, an alternating current may be driven through thecoil 12 and an amplitude and phase shift of the resulting voltage can be determined. Likewise, thecoil 12 can be connected to a capacitor having a known capacitance to form a resonator whose resonance frequency can be determined by wobbling or by applying a pulse signal and analyzing the answer signal. The inductance can then be calculated from the determined resonance frequency. Likewise, thecoil 12 can be connected as part of a bridge network, e. g. a Maxwell bridge for determining the resonance frequency. - As the inductance is much higher in the
coils 12 in which one of the terminal pole shoes 16 is located as opposed to thecoils 12 where one of theother pole shoes 15 is located, the axial position of thearmature 8 and hence the already dispensed dose and/or the dose remaining in thecartridge 4 can be determined. - The inductance of the
coils 12 may be determined by the same voltage used to apply the thrust force FT to thearmature 8. - In alternative non-illustrated embodiments the
drive unit 5 may be arranged without the geometrical differences between the pole shoes 15 and terminal pole shoes 16 but with the above describeddifferent air gaps 21 of thefirst group 19 and thesecond group 20. - The term “drug” or “medicament”, as used herein, means a pharmaceutical formulation containing at least one pharmaceutically active compound,
- wherein in one embodiment the pharmaceutically active compound has a molecular weight up to 1500 Da and/or is a peptide, a protein, a polysaccharide, a vaccine, a DNA, a RNA, an enzyme, an antibody or a fragment thereof, a hormone or an oligonucleotide, or a mixture of the above-mentioned pharmaceutically active compound,
- wherein in a further embodiment the pharmaceutically active compound is useful for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis,
- wherein in a further embodiment the pharmaceutically active compound comprises at least one peptide for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy,
- wherein in a further embodiment the pharmaceutically active compound comprises at least one human insulin or a human insulin analogue or derivative, glucagon-like peptide (GLP-1) or an analogue or derivative thereof, or exendin-3 or exendin-4 or an analogue or derivative of exendin-3 or exendin-4.
- Insulin analogues are for example Gly(A21), Arg(B31), Arg(B32) human insulin; Lys(B3), Glu(B29) human insulin; Lys(B28), Pro(B29) human insulin; Asp(B28) human insulin; human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.
- Insulin derivatives are for example B29-N-myristoyl-des(B30) human insulin; B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl- ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-Y-glutamyl)-des(B30) human insulin; B29-N-(N-lithocholyl-Y-glutamyl)-des(B30) human insulin; B29-N-(w-carboxyheptadecanoyl)-des(B30) human insulin and B29-N-(ω-carboxyheptadecanoyl) human insulin.
- Exendin-4 for example means Exendin-4(1-39), a peptide of the sequence H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-lle-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2.
- Exendin-4 derivatives are for example selected from the following list of compounds:
- H-(Lys)4-des Pro36, des Pro37 Exendin-4(1-39)-NH2,
- H-(Lys)5-des Pro36, des Pro37 Exendin-4(1-39)-NH2,
- des Pro36 Exendin-4(1-39),
- des Pro36 [Asp28] Exendin-4(1-39),
- des Pro36 [lsoAsp28] Exendin-4(1-39),
- des Pro36 [Met(O)14, Asp28] Exendin-4(1-39),
- des Pro36 [Met(O)14, IsoAsp28] Exendin-4(1-39),
- des Pro36 [Trp(O2)25, Asp28] Exendin-4(1-39),
- des Pro36 [Trp(O2)25, IsoAsp28] Exendin-4(1-39),
- des Pro36 [Met(O)14 Trp(O2)25, Asp28] Exendin-4(1-39),
- des Pro36 [Met(O)14 Trp(O2)25, IsoAsp28] Exendin-4(1-39); or
- des Pro36 [Asp28] Exendin-4(1-39),
- des Pro36 [lsoAsp28] Exendin-4(1-39),
- des Pro36 [Met(O)14, Asp28] Exendin-4(1-39),
- des Pro36 [Met(O)14, IsoAsp28] Exendin-4(1-39),
- des Pro36 [Trp(O2)25, Asp28] Exendin-4(1-39),
- des Pro36 [Trp(O2)25, IsoAsp28] Exendin-4(1-39),
- des Pro36 [Met(O)14 Trp(O2)25, Asp28] Exendin-4(1-39),
- des Pro36 [Met(O)14 Trp(O2)25, IsoAsp28] Exendin-4(1-39),
- wherein the group -Lys6-NH2 may be bound to the C-terminus of the Exendin-4 derivative;
- or an Exendin-4 derivative of the sequence
- des Pro36 Exendin-4(1-39)-Lys6-NH2 (AVE0010),
- H-(Lys)6-des Pro36 [Asp28] Exendin-4(1-39)-Lys6-NH2,
- des Asp28 Pro36, Pro37, Pro38Exendin-4(1-39)-NH2,
- H-(Lys)6-des Pro36, Pro38 [Asp28] Exendin-4(1-39)-NH2,
- H-Asn-(Glu)5des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-NH2,
- des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-(Lys)6-NH2,
- H-(Lys)6-des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-(Lys)6-NH2,
- H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-(Lys)6-NH2,
- H-(Lys)6-des Pro36 [Trp(O2)25, Asp28] Exendin-4(1-39)-Lys6-NH2,
- H-des Asp28 Pro36, Pro37, Pro38 [Trp(O2)25] Exendin-4(1-39)-NH2,
- H-(Lys)6-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-NH2,
- H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-NH2,
- des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
- H-(Lys)6-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
- H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
- H-(Lys)6-des Pro36 [Met(O)14, Asp28] Exendin-4(1-39)-Lys6-NH2,
- des Met(O)14 Asp28 Pro36, Pro37, Pro38 Exendin-4(1-39)-NH2,
- H-(Lys)6-desPro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-NH2,
- H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-NH2,
- des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
- H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
- H-Asn-(Glu)5 des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
- H-Lys6-des Pro36 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(1-39)-Lys6-NH2,
- H-des Asp28 Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25] Exendin-4(1-39)-NH2,
- H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-NH2,
- H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(1-39)-NH2,
- des Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
- H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(S1-39)-(Lys)6-NH2,
- H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2;
- or a pharmaceutically acceptable salt or solvate of any one of the afore-mentioned Exendin-4 derivative.
- Hormones are for example hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists as listed in Rote Liste, ed. 2008, Chapter 50, such as Gonadotropine (Follitropin, Lutropin, Choriongonadotropin, Menotropin), Somatropine (Somatropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Leuprorelin, Buserelin, Nafarelin, Goserelin.
- A polysaccharide is for example a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra low molecular weight heparin or a derivative thereof, or a sulphated, e.g. a poly-sulphated form of the above-mentioned polysaccharides, and/or a pharmaceutically acceptable salt thereof. An example of a pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium.
- Antibodies are globular plasma proteins (~150 kDa) that are also known as immunoglobulins which share a basic structure. As they have sugar chains added to amino acid residues, they are glycoproteins. The basic functional unit of each antibody is an immunoglobulin (Ig) monomer (containing only one Ig unit); secreted antibodies can also be dimeric with two Ig units as with IgA, tetrameric with four Ig units like teleost fish IgM, or pentameric with five Ig units, like mammalian IgM.
- The Ig monomer is a “Y”-shaped molecule that consists of four polypeptide chains; two identical heavy chains and two identical light chains connected by disulfide bonds between cysteine residues. Each heavy chain is about 440 amino acids long; each light chain is about 220 amino acids long. Heavy and light chains each contain intrachain disulfide bonds which stabilize their folding. Each chain is composed of structural domains called Ig domains. These domains contain about 70-110 amino acids and are classified into different categories (for example, variable or V, and constant or C) according to their size and function. They have a characteristic immunoglobulin fold in which two β sheets create a “sandwich” shape, held together by interactions between conserved cysteines and other charged amino acids.
- There are five types of mammalian Ig heavy chain denoted by α, δ, ε, γ, and µ. The type of heavy chain present defines the isotype of antibody; these chains are found in IgA, IgD, IgE, IgG, and IgM antibodies, respectively.
- Distinct heavy chains differ in size and composition; α and γ contain approximately 450 amino acids and δ approximately 500 amino acids, while µ and ε have approximately 550 amino acids. Each heavy chain has two regions, the constant region (CH) and the variable region (VH). In one species, the constant region is essentially identical in all antibodies of the same isotype, but differs in antibodies of different isotypes. Heavy chains γ, a and δ have a constant region composed of three tandem Ig domains, and a hinge region for added flexibility; heavy chains µ and ε have a constant region composed of four immunoglobulin domains. The variable region of the heavy chain differs in antibodies produced by different B cells, but is the same for all antibodies produced by a single B cell or B cell clone. The variable region of each heavy chain is approximately 110 amino acids long and is composed of a single Ig domain.
- In mammals, there are two types of immunoglobulin light chain denoted by λ and K. A light chain has two successive domains: one constant domain (CL) and one variable domain (VL). The approximate length of a light chain is 211 to 217 amino acids. Each antibody contains two light chains that are always identical; only one type of light chain, K or λ, is present per antibody in mammals.
- Although the general structure of all antibodies is very similar, the unique property of a given antibody is determined by the variable (V) regions, as detailed above. More specifically, variable loops, three each the light (VL) and three on the heavy (VH) chain, are responsible for binding to the antigen, i.e. for its antigen specificity. These loops are referred to as the Complementarity Determining Regions (CDRs). Because CDRs from both VH and VL domains contribute to the antigen-binding site, it is the combination of the heavy and the light chains, and not either alone, that determines the final antigen specificity.
- An “antibody fragment” contains at least one antigen binding fragment as defined above, and exhibits essentially the same function and specificity as the complete antibody of which the fragment is derived from. Limited proteolytic digestion with papain cleaves the Ig prototype into three fragments. Two identical amino terminal fragments, each containing one entire L chain and about half an H chain, are the antigen binding fragments (Fab). The third fragment, similar in size but containing the carboxyl terminal half of both heavy chains with their interchain disulfide bond, is the crystalizable fragment (Fc). The Fc contains carbohydrates, complement-binding, and FcR-binding sites. Limited pepsin digestion yields a single F(ab′)2 fragment containing both Fab pieces and the hinge region, including the H-H interchain disulfide bond. F(ab′)2 is divalent for antigen binding. The disulfide bond of F(ab′)2 may be cleaved in order to obtain Fab′. Moreover, the variable regions of the heavy and light chains can be fused together to form a single chain variable fragment (scFv).
- Pharmaceutically acceptable salts are for example acid addition salts and basic salts. Acid addition salts are e.g. HCl or HBr salts. Basic salts are e.g. salts having a cation selected from alkali or alkaline, e.g. Na+, or K+, or Ca2+, or an ammonium ion N+(R1)(R2)(R3)(R4), wherein R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1-C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10-heteroaryl group. Further examples of pharmaceutically acceptable salts are described in “Remington’s Pharmaceutical Sciences” 17. ed. Alfonso R. Gennaro (Ed.), Mark Publishing Company, Easton, Pa., U.S.A., 1985 and in Encyclopedia of Pharmaceutical Technology.
- Pharmaceutically acceptable solvates are for example hydrates.
- Those of skill in the art will understand that modifications (additions and/or removals) of various components of the apparatuses, methods and/or systems and embodiments described herein may be made without departing from the full scope and spirit of the present disclosure, which encompass such modifications and any and all equivalents thereof.
-
List of References 1 drug delivery device 2 case 3 holder 4 cartridge 5 drive unit 6 stopper 7 stator 8 armature 9 tube 12 coil 13 metal sheet 14 magnet 15 pole shoe 16 terminal pole shoe 17 axle 19 first group 20 second group 21 air gap 22 notch dl inner diameter D distal direction F force FL latching force FT thrust force L axial position P proximal direction R restriction line
Claims (21)
1-15. (canceled)
16. A method, comprising:
initiating supply of current through a plurality of coils of a stator to apply a thrust force on an armature, thereby causing a stopper of a drug delivery device to translate distally to dispense a dose of a medicament;
measuring an inductance of a first coil of the plurality of coils;
determining a dispensed dose of the medicament or an amount of medicament remaining in a cartridge based on the measured inductance; and
determining an axial position of the armature within the stator by determining an inductance for each coil of the plurality of coils.
17. The method according to claim 16 , wherein initiating the supply of current comprises:
initiating the supply of current through the plurality of coils such that the armature is advanced axially from an initial position; and
ceasing the supply of current through the plurality of coils such that the armature returns to the initial position.
18. The method according to claim 16 , wherein the dispensed dose is determined based on the axial position of the armature within the stator.
19. The method according to claim 16 , wherein the inductance determined for each coil of the plurality of coils is determined using a control unit connected to each coil of the plurality of coils.
20. The method according to claim 16 , wherein measuring the inductance comprises applying an alternating voltage to the first coil.
21. The method according to claim 16 , wherein measuring the inductance comprises applying an alternating current to the first coil.
22. The method according to claim 16 , wherein measuring the inductance comprises: connecting the first coil to a capacitor having a capacitance to form a resonator; and determining a resonance frequency of the capacitor.
23. The method according to claim 16 , wherein measuring the inductance comprises using a bridge network connected to the first coil.
24. The method according to claim 16 , wherein:
the armature comprises a plurality of magnets and a plurality of pole shoes consecutively arranged in an axial direction;
a respective pole shoe of the plurality of poles shoes is arranged between respectively neighboring magnets of the plurality of magnets; and
at least one axial end of the armature comprises a terminal pole shoe.
25. The method according to claim 16 , wherein the thrust force is 20 N.
26. The method according to claim 16 , wherein determining the dispensed dose comprises measuring a fluctuation of the inductance of the first coil.
27. The method according to claim 16 , wherein:
the first coil comprises a cylindrical coil, and
the measured inductance is based on a number N of windings, a magnetic field constant λ0, a relative permeability µr, and the internal cross-sectional area A of the cylindrical coil.
28. The method according to claim 16 , wherein:
the first coil comprises a cylindrical coil, and
the measured inductance is based on a number N of windings, a magnetic field constant λ0, a relative permeability µr, an internal cross-sectional area A of the cylindrical coil, and a radius of a winding rW.
29. The method according to claim 16 , wherein, to apply the thrust force, the coils of the plurality of coils are supplied with an alternating or pulsed current such that magnetic fields are induced in the coils of the plurality of coils and interact with a static magnetic field generated by one or more magnets of the armature.
30. The method according to claim 16 , wherein the inductance of the first coil is measured using a voltage used to apply the thrust force to the armature.
31. The method according to claim 16 , wherein the armature moves to a zero position when the coils of the plurality of coils are turned off.
32. A method, comprising:
initiating supply of current through a plurality of coils of a stator to apply a thrust force on an armature, thereby causing a stopper of a drug delivery device to translate distally to dispense a dose of a medicament;
measuring an inductance of a coil of the plurality of coils by applying an alternating voltage to the coil; and
determining a dispensed dose of the medicament or an amount of medicament remaining in a cartridge based on the measured inductance.
33. The method according to claim 32 , wherein measuring the inductance further comprises determining an amplitude and phase shift of a current in the coil.
34. The method according to claim 32 , wherein:
the armature comprises a plurality of magnets and a plurality of pole shoes consecutively arranged in an axial direction;
a respective pole shoe of the plurality of poles shoes is arranged between respectively neighboring magnets of the plurality of magnets; and
at least one axial end of the armature comprises a terminal pole shoe.
35. A method, comprising:
initiating supply of current through a plurality of coils of a stator to apply a thrust force on an armature, thereby causing a stopper of a drug delivery device to translate distally to dispense a dose of a medicament;
measuring an inductance of a coil of the plurality of coils by connecting the coil to a capacitor having a capacitance to form a resonator and determining a resonance frequency of the capacitor; and
determining a dispensed dose of the medicament or an amount of medicament remaining in a cartridge based on the measured inductance.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/337,625 US20230330325A1 (en) | 2014-12-22 | 2023-06-20 | Drug delivery device with electromagnetic drive unit |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14199552.2 | 2014-12-22 | ||
EP14199552 | 2014-12-22 | ||
PCT/EP2015/080674 WO2016102407A1 (en) | 2014-12-22 | 2015-12-18 | Drug delivery device with electromagnetic drive unit |
US201715538729A | 2017-06-22 | 2017-06-22 | |
US15/930,132 US11717607B2 (en) | 2014-12-22 | 2020-05-12 | Drug delivery device with electromagnetic drive unit |
US18/337,625 US20230330325A1 (en) | 2014-12-22 | 2023-06-20 | Drug delivery device with electromagnetic drive unit |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/930,132 Continuation US11717607B2 (en) | 2014-12-22 | 2020-05-12 | Drug delivery device with electromagnetic drive unit |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230330325A1 true US20230330325A1 (en) | 2023-10-19 |
Family
ID=52278419
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/538,729 Active 2036-08-28 US10682459B2 (en) | 2014-12-22 | 2015-12-18 | Drug delivery device with electromagnetic drive unit |
US15/930,132 Active 2037-08-26 US11717607B2 (en) | 2014-12-22 | 2020-05-12 | Drug delivery device with electromagnetic drive unit |
US18/337,625 Pending US20230330325A1 (en) | 2014-12-22 | 2023-06-20 | Drug delivery device with electromagnetic drive unit |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/538,729 Active 2036-08-28 US10682459B2 (en) | 2014-12-22 | 2015-12-18 | Drug delivery device with electromagnetic drive unit |
US15/930,132 Active 2037-08-26 US11717607B2 (en) | 2014-12-22 | 2020-05-12 | Drug delivery device with electromagnetic drive unit |
Country Status (6)
Country | Link |
---|---|
US (3) | US10682459B2 (en) |
EP (1) | EP3237044B1 (en) |
JP (1) | JP6772175B2 (en) |
CN (1) | CN107635602B (en) |
DK (1) | DK3237044T3 (en) |
WO (1) | WO2016102407A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3519021A1 (en) | 2016-10-03 | 2019-08-07 | Tecpharma Licensing AG | Electronic module for monitoring injection devices |
CH713114A2 (en) | 2016-11-09 | 2018-05-15 | Tecpharma Licensing Ag | Electronic add-on module for injection devices. |
CN108452405B (en) * | 2017-02-20 | 2022-04-08 | 新加坡国立大学 | Electromagnetic driving device for needle-free injection |
US10946143B2 (en) | 2017-05-25 | 2021-03-16 | West Pharmaceutical Services, Inc. | Detection and communication of plunger position using induction |
JP7027458B2 (en) | 2017-06-06 | 2022-03-01 | ウエスト ファーマスーティカル サービシーズ インコーポレイテッド | Elastomer article with embedded electronic device and its manufacturing method |
US20200360611A1 (en) * | 2017-11-10 | 2020-11-19 | Cc - Pharma Gmbh | Method and device for the needle-free injecting of fluid into a substrate, and fluid container for use in the method and the device |
EP3545993A1 (en) | 2018-03-29 | 2019-10-02 | Tecpharma Licensing AG | Status indicator for drug delivery systems |
EP3545992A1 (en) * | 2018-03-29 | 2019-10-02 | Tecpharma Licensing AG | State estimation for drug delivery systems |
WO2020188453A1 (en) * | 2019-03-15 | 2020-09-24 | CorWave SA | Systems and methods for controlling an implantable blood pump |
JP6964639B2 (en) * | 2019-10-02 | 2021-11-10 | 本田技研工業株式会社 | Electric suspension device |
JP2023069190A (en) * | 2021-11-05 | 2023-05-18 | クロノファング株式会社 | linear motor |
WO2023170195A1 (en) * | 2022-03-11 | 2023-09-14 | Sanofi | Drive mechanism for a drug delivery device |
WO2023170199A1 (en) * | 2022-03-11 | 2023-09-14 | Sanofi | Drive mechanism for a drug delivery device |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2550053A (en) * | 1948-04-13 | 1951-04-24 | Becton Dickinson Co | Injection device |
GB686343A (en) * | 1950-09-26 | 1953-01-21 | Becton Dickinson Co | Improvements relating to hypodermic injection devices |
US4965864A (en) * | 1987-12-07 | 1990-10-23 | Roth Paul E | Linear motor |
US5990162A (en) | 1997-08-29 | 1999-11-23 | Orphan Medical, Inc. | Method for treatment of fibromyalgia and chronic fatigue syndrome |
EP1023763A2 (en) | 1997-10-15 | 2000-08-02 | Advanced Motion Technologies LLC | A linear electromagnetic machine |
GB2358967A (en) * | 2000-01-26 | 2001-08-08 | Phillip Michael Raymond Denne | Tapered pole pieces for a linear electromagnetic machine |
EP1150416B1 (en) * | 2000-03-17 | 2007-08-22 | Festo AG & Co | Electrodynamic direct drive of a linear motor |
DE10229689A1 (en) * | 2002-06-27 | 2004-01-22 | Universität Stuttgart | Integrated displacement measurement in d.c. linear motors with alternating permanent magnets and flux guide points involves carrying out impedance measurement on complete motor lines |
WO2006045523A1 (en) * | 2004-10-21 | 2006-05-04 | Novo Nordisk A/S | Medication delivery system with a detector for providing a signal indicative of an amount of an ejected dose of drug |
CN102247637A (en) * | 2010-05-19 | 2011-11-23 | 北京快舒尔医疗技术有限公司 | Battery-powered miniature electric needleless syringe |
JP5743785B2 (en) * | 2011-07-28 | 2015-07-01 | 日立オートモティブシステムズ株式会社 | Electromagnetic suspension |
JP5927063B2 (en) | 2012-06-27 | 2016-05-25 | Kyb株式会社 | Linear actuator and tube assembly method for linear actuator |
CN105103422A (en) | 2013-04-12 | 2015-11-25 | 三菱电机株式会社 | Movable element and linear motor |
WO2014180804A2 (en) * | 2013-05-07 | 2014-11-13 | Sanofi-Aventis Deutschland Gmbh | Apparatus employing coil inductance determination and method for operating the apparatus |
CN103816585B (en) * | 2014-02-28 | 2016-06-22 | 华南理工大学 | A kind of mechanical type Needleless injection pressue device |
WO2015172681A1 (en) * | 2014-05-14 | 2015-11-19 | 苏州大学张家港工业技术研究院 | Electromagnetic accumulating needleless syringe |
-
2015
- 2015-12-18 EP EP15810790.4A patent/EP3237044B1/en active Active
- 2015-12-18 DK DK15810790T patent/DK3237044T3/en active
- 2015-12-18 JP JP2017551013A patent/JP6772175B2/en active Active
- 2015-12-18 CN CN201580070994.7A patent/CN107635602B/en active Active
- 2015-12-18 US US15/538,729 patent/US10682459B2/en active Active
- 2015-12-18 WO PCT/EP2015/080674 patent/WO2016102407A1/en active Application Filing
-
2020
- 2020-05-12 US US15/930,132 patent/US11717607B2/en active Active
-
2023
- 2023-06-20 US US18/337,625 patent/US20230330325A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US10682459B2 (en) | 2020-06-16 |
EP3237044A1 (en) | 2017-11-01 |
CN107635602B (en) | 2021-03-30 |
US11717607B2 (en) | 2023-08-08 |
JP2018501051A (en) | 2018-01-18 |
EP3237044B1 (en) | 2019-08-28 |
WO2016102407A1 (en) | 2016-06-30 |
US20170368256A1 (en) | 2017-12-28 |
US20200268964A1 (en) | 2020-08-27 |
CN107635602A (en) | 2018-01-26 |
JP6772175B2 (en) | 2020-10-21 |
DK3237044T3 (en) | 2019-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230330325A1 (en) | Drug delivery device with electromagnetic drive unit | |
US10857295B2 (en) | Medicament delivery device | |
US11638786B2 (en) | Medicament delivery device | |
US10173012B2 (en) | Medicament delivery device with two drive springs | |
EP2885024B1 (en) | Injection device | |
US10279130B2 (en) | Medicament delivery device with medicament delivery initiation indicator | |
US11904153B2 (en) | Medicament delivery device with use indicator | |
EP2866862B1 (en) | Drug delivery device | |
EP3024515B1 (en) | Drive unit for a drug delivery device | |
US20150018779A1 (en) | Spring assembly for a drug delivery device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NESSEL, CHRISTIAN;RICHTER, RENE;WITT, ROBERT;AND OTHERS;SIGNING DATES FROM 20160120 TO 20160203;REEL/FRAME:064017/0663 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION UNDERGOING PREEXAM PROCESSING |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |